Altimmune (NASDAQ:ALT – Get Free Report) and Caribou Biosciences (NASDAQ:CRBU – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.
Profitability
This table compares Altimmune and Caribou Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Altimmune | N/A | -29.26% | -25.48% |
| Caribou Biosciences | -1,085.00% | -102.74% | -69.45% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Altimmune and Caribou Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Altimmune | 1 | 1 | 8 | 0 | 2.70 |
| Caribou Biosciences | 1 | 4 | 1 | 1 | 2.29 |
Altimmune presently has a consensus target price of $14.33, indicating a potential upside of 916.55%. Caribou Biosciences has a consensus target price of $4.50, indicating a potential upside of 1,346.95%. Given Caribou Biosciences’ higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Altimmune.
Insider & Institutional Ownership
78.0% of Altimmune shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 1.6% of Altimmune shares are held by insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Altimmune and Caribou Biosciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Altimmune | $40,000.00 | 6,859.30 | -$88.09 million | ($0.72) | -1.96 |
| Caribou Biosciences | $11.16 million | 3.01 | -$148.12 million | ($1.03) | -0.30 |
Altimmune has higher earnings, but lower revenue than Caribou Biosciences. Altimmune is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Altimmune has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.5, suggesting that its stock price is 150% more volatile than the S&P 500.
Summary
Altimmune beats Caribou Biosciences on 9 of the 15 factors compared between the two stocks.
About Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.
About Caribou Biosciences
Caribou Biosciences, Inc. is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. Its work focuses on allogeneic, or donor-derived, CAR-T cell treatments designed to be manufactured for use by multiple patients. The company uses its chRDNA genome-editing platform, which combines CRISPR RNA with DNA components, to make targeted changes to cells. Its clinical programs include CAR-T candidates directed at targets such as CD19 and BCMA, which are being developed for certain blood cancers.
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
